$INSY Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Insys Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Insys Therapeutics, Inc.. Get notifications about new insider transactions in Insys Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 06 2019 | INSY | Insys Therapeutics ... | Housley Andrece | Chief Financial Off ... | Option Exercise | A | 4.30 | 31,008 | 133,334 | 31,008 | |
| Jun 06 2019 | INSY | Insys Therapeutics ... | Housley Andrece | Chief Financial Off ... | Grant | A | 0.00 | 3,992 | 0 | 20,994 | 17 K to 21 K (+23.48 %) |
| Jun 05 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Executive Off ... | Option Exercise | A | 4.30 | 72,674 | 312,498 | 72,674 | |
| Jun 05 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Executive Off ... | Grant | A | 0.00 | 12,475 | 0 | 62,075 | 49.6 K to 62.1 K (+25.15 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 3.81 | 282,152 | 1,074,999 | 282,152 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 8.06 | 64,000 | 515,840 | 64,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 59,206 | 0 | 130,192 | 71 K to 130.2 K (+83.41 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 16,000 | 0 | 70,986 | 55 K to 71 K (+29.10 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 3.81 | 173,000 | 659,130 | 173,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 8.06 | 42,400 | 341,744 | 42,400 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 29,000 | 0 | 49,600 | 20.6 K to 49.6 K (+140.78 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 10,600 | 0 | 20,600 | 10 K to 20.6 K (+106.00 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 8,083 | 0 | 68,166 | 60.1 K to 68.2 K (+13.45 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 4,000 | 0 | 60,083 | 56.1 K to 60.1 K (+7.13 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 8,083 | 0 | 18,083 | 10 K to 18.1 K (+80.83 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 4,000 | 0 | 10,000 | 6 K to 10 K (+66.67 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 8,083 | 0 | 24,083 | 16 K to 24.1 K (+50.52 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 6,000 | 0 | 16,000 | 10 K to 16 K (+60.00 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Option Exercise | A | 3.81 | 70,000 | 266,700 | 70,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 5.96 | 24,000 | 143,040 | 24,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Apr 23 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Option Exercise | A | 3.81 | 70,000 | 266,700 | 70,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 5.96 | 24,000 | 143,040 | 24,000 | |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 23 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 8,083 | 0 | 24,083 | 16 K to 24.1 K (+50.52 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 6,000 | 0 | 16,000 | 10 K to 16 K (+60.00 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 3.81 | 173,000 | 659,130 | 173,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 8.06 | 42,400 | 341,744 | 42,400 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 29,000 | 0 | 49,600 | 20.6 K to 49.6 K (+140.78 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 10,600 | 0 | 20,600 | 10 K to 20.6 K (+106.00 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 3.81 | 282,152 | 1,074,999 | 282,152 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 8.06 | 64,000 | 515,840 | 64,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 59,206 | 0 | 130,192 | 71 K to 130.2 K (+83.41 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 16,000 | 0 | 70,986 | 55 K to 71 K (+29.10 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Option Exercise | A | 3.81 | 70,000 | 266,700 | 70,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 8,083 | 0 | 18,083 | 10 K to 18.1 K (+80.83 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 4,000 | 0 | 10,000 | 6 K to 10 K (+66.67 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 8,083 | 0 | 68,166 | 60.1 K to 68.2 K (+13.45 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 4,000 | 0 | 60,083 | 56.1 K to 60.1 K (+7.13 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 5.96 | 24,000 | 143,040 | 24,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 8,083 | 0 | 24,083 | 16 K to 24.1 K (+50.52 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 6,000 | 0 | 16,000 | 10 K to 16 K (+60.00 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 3.81 | 173,000 | 659,130 | 173,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 8.06 | 42,400 | 341,744 | 42,400 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 29,000 | 0 | 49,600 | 20.6 K to 49.6 K (+140.78 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 10,600 | 0 | 20,600 | 10 K to 20.6 K (+106.00 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 3.81 | 282,152 | 1,074,999 | 282,152 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 8.06 | 64,000 | 515,840 | 64,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 59,206 | 0 | 130,192 | 71 K to 130.2 K (+83.41 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 16,000 | 0 | 70,986 | 55 K to 71 K (+29.10 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Option Exercise | A | 3.81 | 70,000 | 266,700 | 70,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Grant | A | 0.00 | 10,000 | 0 | 25,000 | 15 K to 25 K (+66.67 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 8,083 | 0 | 18,083 | 10 K to 18.1 K (+80.83 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 4,000 | 0 | 10,000 | 6 K to 10 K (+66.67 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | A | 8.06 | 16,000 | 128,960 | 16,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 8,083 | 0 | 68,166 | 60.1 K to 68.2 K (+13.45 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 4,000 | 0 | 60,083 | 56.1 K to 60.1 K (+7.13 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 6.36 | 20,935 | 133,147 | 20,935 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Option Exercise | A | 5.96 | 24,000 | 143,040 | 24,000 | |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 8,083 | 0 | 14,083 | 6 K to 14.1 K (+134.72 %) |
| Apr 19 2019 | INSY | Insys Therapeutics ... | Vanhove Geertrui | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Oct 12 2018 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Option Exercise | A | 8.61 | 100,000 | 861,000 | 100,000 | |
| Oct 12 2018 | INSY | Insys Therapeutics ... | Nance Mark E | Chief Legal Officer ... | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
| Aug 09 2018 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Option Exercise | A | 6.65 | 24,000 | 159,600 | 24,000 | |
| Aug 09 2018 | INSY | Insys Therapeutics ... | BOHLEN ELIZABETH | Director | Grant | A | 0.00 | 6,000 | 0 | 6,000 | 0 to 6 K |
| Aug 07 2018 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | D | 0.00 | 5,000 | 0 | 10,000 | |
| Aug 07 2018 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Option Exercise | M | 3.63 | 60,000 | 217,800 | 0 | |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Option Exercise | M | 1.62 | 68,850 | 111,537 | 0 | |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Option Exercise | M | 0.61 | 33,654 | 20,529 | 0 | |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Option Exercise | D | 0.00 | 4,000 | 0 | 0 | |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Sell | S | 6.41 | 166,504 | 1,067,291 | 0 | 166.5 K to 0 (-100.00 %) |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Buy | M | 3.63 | 60,000 | 217,800 | 166,504 | 106.5 K to 166.5 K (+56.34 %) |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Buy | M | 1.62 | 68,850 | 111,537 | 106,504 | 37.7 K to 106.5 K (+182.85 %) |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Buy | M | 0.61 | 33,654 | 20,529 | 37,654 | 4 K to 37.7 K (+841.35 %) |
| May 14 2018 | INSY | Insys Therapeutics ... | Tambi Brian | Director | Grant | A | 0.00 | 4,000 | 0 | 4,000 | 0 to 4 K |
| May 10 2018 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Option Exercise | D | 0.00 | 6,000 | 0 | 0 | |
| May 10 2018 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Grant | A | 0.00 | 6,000 | 0 | 10,000 | 4 K to 10 K (+150.00 %) |
| May 10 2018 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Option Exercise | D | 0.00 | 4,000 | 0 | 0 | |
| May 10 2018 | INSY | Insys Therapeutics ... | LAPALME PIERRE | Director | Grant | A | 0.00 | 4,000 | 0 | 6,000 | 2 K to 6 K (+200.00 %) |
| May 10 2018 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | D | 0.00 | 4,000 | 0 | 0 | |
| May 10 2018 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 4,000 | 0 | 56,083 | 52.1 K to 56.1 K (+7.68 %) |
| May 10 2018 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Option Exercise | D | 0.00 | 4,000 | 0 | 0 | |
| May 10 2018 | INSY | Insys Therapeutics ... | MEYER STEVEN J | Director | Grant | A | 0.00 | 4,000 | 0 | 56,083 | 52.1 K to 56.1 K (+7.68 %) |
| Apr 17 2018 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | D | 0.00 | 11,000 | 0 | 22,000 | |
| Apr 17 2018 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Grant | A | 0.00 | 11,000 | 0 | 26,400 | 15.4 K to 26.4 K (+71.43 %) |
| Mar 01 2018 | INSY | Insys Therapeutics ... | JOHN N KAPOOR TRUST DATED SEPT ... | 10% Owner | Sell | Z | 0.00 | 56,288 | 0 | 56,288 | 112.6 K to 56.3 K (-50.00 %) |
| Mar 01 2018 | INSY | Insys Therapeutics ... | JOHN N KAPOOR TRUST DATED SEPT ... | 10% Owner | Sell | Z | 0.00 | 31,982 | 0 | 31,982 | 64 K to 32 K (-50.00 %) |
| Mar 01 2018 | INSY | Insys Therapeutics ... | JOHN N KAPOOR TRUST DATED SEPT ... | 10% Owner | Sell | Z | 0.00 | 42,447,810 | 0 | 42,447,810 | 84.9 M to 42.4 M (-50.00 %) |
| Feb 22 2018 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Feb 22 2018 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 9.80 | 24,000 | 235,200 | 24,000 | |
| Feb 22 2018 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Feb 22 2018 | INSY | Insys Therapeutics ... | Mahboob Vaseem | Director | Option Exercise | A | 9.80 | 24,000 | 235,200 | 24,000 | |
| Nov 21 2017 | INSY | Insys Therapeutics ... | Del Fosse Franc | General Counsel | Option Exercise | A | 5.37 | 25,000 | 134,250 | 25,000 | |
| Nov 21 2017 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 5.37 | 15,000 | 80,550 | 15,000 | |
| Nov 21 2017 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Option Exercise | A | 5.37 | 40,000 | 214,800 | 40,000 | |
| Aug 17 2017 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Aug 17 2017 | INSY | Insys Therapeutics ... | Long Andrew G | Chief Financial Off ... | Option Exercise | A | 9.97 | 100,000 | 997,000 | 100,000 | |
| Aug 14 2017 | INSY | Insys Therapeutics ... | JOHN N KAPOOR TRUST DATED SEPT ... | 10% Owner | Buy | P | 8.93 | 17,500 | 156,338 | 42,447,810 | 42.4 M to 42.4 M (+0.04 %) |
| Aug 10 2017 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Buy | P | 8.92 | 5,500 | 49,056 | 15,400 | 9.9 K to 15.4 K (+55.56 %) |
| Aug 04 2017 | INSY | Insys Therapeutics ... | FOURTEAU PATRICK | Director | Option Exercise | M | 1.62 | 10,000 | 16,200 | 63,770 | |
| Aug 04 2017 | INSY | Insys Therapeutics ... | FOURTEAU PATRICK | Director | Buy | M | 1.62 | 10,000 | 16,200 | 69,682 | 59.7 K to 69.7 K (+16.76 %) |
| Aug 04 2017 | INSY | Insys Therapeutics ... | Del Fosse Franc | General Counsel | Option Exercise | A | 0.00 | 8,000 | 0 | 8,000 | |
| Jun 14 2017 | INSY | Insys Therapeutics ... | Motahari Saeed | President & CEO | Buy | P | 11.10 | 5,400 | 59,955 | 9,900 | 4.5 K to 9.9 K (+120.00 %) |
| Jun 02 2017 | INSY | Insys Therapeutics ... | Vishnoi Rohit | Director | Buy | P | 14.14 | 4,000 | 56,575 | 4,000 | 0 to 4 K |
| May 26 2017 | INSY | Insys Therapeutics ... | FOURTEAU PATRICK | Director | Option Exercise | M | 3.63 | 10,000 | 36,300 | 50,000 | |
| May 26 2017 | INSY | Insys Therapeutics ... | FOURTEAU PATRICK | Director | Buy | M | 3.63 | 10,000 | 36,300 | 59,682 | 49.7 K to 59.7 K (+20.13 %) |